[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574282":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":10,"maxAge":10,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"fostamatinib treatmented",null,[12],"Drug: fostamatinib",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","fostamatinib","oral administration",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Kazunori Abe, director","CONTACT","0356843575","rinsyousiken@pharm.kissei.co.jp",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":10,"geoPoint":10,"contacts":32},"Research site","RECRUITING","Tokyo and Japanese Other Cities","Japan","JP",[33],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100574282","special-drug-use-results-survey-for-long-term-use-fostamatinib-100574282",false,"NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.","ALL",{"count":44,"type":45},149,"ESTIMATED","18 Months","OBSERVATIONAL","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.",[50],"Chronic Idiopathic Thrombocytopenic Purpura","2024-12-26",{"date":53,"type":54},"2025-01-03","ACTUAL",{"date":56,"type":54},"2023-05-29",{"date":58,"type":45},"2028-09-30",{"name":5,"class":6},1]